This is a default text for your page IntronA (Interferon alpha 2b). Click above on edit this page to modify. Be careful with the < and > signs.
You may include any references to papers as in: the use of JSmol in Proteopedia [2] or to the article describing Jmol [3] to the rescue.
Function
IFNα2b is a naturally secreted protein that is produced by the human body via antigen-presenting cells (APCs) [4]. When introduced to the body for treatment, IFNα2b is injected into the body subcutaneously and binds to the surface of cells [5]. When this occurs, IFNα2b produces many possible outcomes. This includes inhibiting replication of viruses within virus-infected cells, suppressing cell proliferation, enhancing activity of macrophages, stimulating certain types of enzymes, and increasing lymphocytes’ specific cytotoxicity [5]. Specifically, in viral infections and malignancy the interferon specifically targets CD8+ effector T cells and CD4+ immunomodulatory T cells to amplify the body’s immune response [4]. It can also help induce a caspase cascade to activate cell death in virally infected and malignant cells [4]. Overall, INFα2b is crucial for activation and regulation of the protective immune response.
Structural highlights
Each IFNα2b monomer consists of five alpha helices and five coiled loops [6]. A zinc molecule is held within each IFNα2b monomer [6]. There are four significant cysteine residues on IFNα2b that create two disulfide bonds [1]. The first disulfide bond is between Cys29 and Cys138 [1]. The second disulfide bond is between Cys1 and Cys98 [1]. IFNα2b is considered a Type I interferon and recognizes interferon alpha receptors 1 and 2 located on the target protein’s surface [1]. Amino acid residues on IFNα2b that participate in binding to IFNAR 1 and 2 are present on one coiled loop and four alpha helices [1]. These residues include: Arg22, Leu26, Phe27, Leu30, Lys31, Arg33, His34, Ser68, Thr79, Lys83, Tyr85, Tyr89, Arg120, Lys121, Gln124, Lys131 Glu132, Arg144, and Glu146 [1].
Mechanism
There are several pathways in that IFNα2b has an effect on the target cell [1]. These pathways include the caspase cascade and the JAK-STAT pathway [1] [4]. The caspase cascade results in apoptosis, thereby participating in both anti-viral and anti-cancer mechanisms [4]. Once IFNα2b binds to either IFNAR 1 or 2 receptors, cytochrome c and tumor necrosis alpha factor trigger the caspase cascade, which in turn signals apoptosis [1]. In the binding of IFNα2b to an IFNAR receptor, the protein JAK (a tyrosine kinase) is activated [1]. JAK is phosphorylated and in turn phosphorylates the IFNAR receptors [1]. The IFNAR receptors bind to STAT proteins resulting in a cascade pathway that signals the release of antiviral proteins [1].
Disease
Hepatitis Virus
Hepatitis C
Hepatitis C (HCV) can range from acute to chronic conditions and progression occurs in more than half of these cases [7]. HCV attacks the liver tissues causing inflammation and cirrhosis, which can lead to chronic liver disease [7]. IFNα2b is used to treat the acute stage of HVC to prevent progression into the chronic disease [7]. IFNα2b overall reduces the viral amplification and allows T-cells to effectively respond to the infection [8].
Hepatitis B
IFNα2b treats chronic Hepatitis B (HBV) by interfering with viral DNA synthesis and enhancing the cellular immune response.7 The cytokine enhances T-cell and natural killer cell activity by interacting with the infected cell’s surface [9]. IFNα2b also activates antiviral enzymes to inhibit proliferation of HBV [9].
Cancer
Multiple Myeloma
IFNα2b has been shown to prolong patients with multiple myeloma [10]. Multiple myeloma is diagnosed when multiple clones of a specific plasma cell are found or when apparent genetic mutations are affecting the cell’s normal functions [10]. IFNα2b therapy causes tumor stabilization and prolongation of the aggressive stage of multiple myeloma with maintained therapy [10].
Hairy cell Leukemia
IFNα2b is a major treatment for patients with hairy cell leukemia [1]. The disease is characterized by B cells in the blood, bone marrow, and spleen [1]. Patients who receive the therapeutic treatment experience partial to complete remission [1]. The treatment is especially effective because there is rarely relapse of the cancer with consistent therapy and mild side effects [1]. The presence of malignant cells decreases, predominantly in the bone marrow, and hematologic levels normalized [11]
